Patent 3,737,433: Scope, Claims, and Landscape Analysis
Patent 3,737,433: U.S. patent assigned to Johnson & Johnson, filed on April 26, 1972, and granted on June 12, 1973. The patent covers a composition for topical application, specifically a hydrophobic, non-aqueous, and semi-solid dermatological preparation for delivering medicaments.
Scope and Claims Overview
Claims Summary:
The patent contains 5 claims, primarily directed at a specific composition:
-
Main Claim:
A topical dermatological composition comprising a medicament dissolved or dispersed in a hydrophobic, semi-solid base consisting of a mixture of oils and waxes, wherein the composition remains stable and retains medicament efficacy over time.
-
Secondary Claims:
- The composition where the base includes fatty acids and their derivatives.
- The composition where the medicament is a steroid or anti-inflammatory agent.
- The composition further includes stabilizing agents to prevent separation of medicament from the base.
- The composition is suitable for extended topical application with sustained release properties.
Claim Scope:
- Focused on semi-solid, hydrophobic, oil-based formulations.
- Intended for delivering medicaments such as steroids, anti-inflammatories, or other drugs soluble in oil phases.
- Emphasizes stability, usability for topical sustained release, and ease of application.
Legal Position:
Claims are narrowly scoped to compositions with specific lipid-based vehicles. The language avoids broad claims on all hydrophobic compositions, instead focusing on particular fatty acid derivatives and specific base formulations.
Patent Landscape
Historical Context
The patent sits within early 1970s pharmacological innovations focusing on topical drug delivery systems. The focus on hydrophobic, semi-solid bases reflects a shift toward formulations that improve drug stability, skin adherence, and controlled release.
Technological Trends
- Lipid-based drug delivery: The claims align with contemporaneous developments in lipid and wax-based carriers.
- Steroid formulations: The inclusion of anti-inflammatory agents points toward the growing need for stable steroid delivery systems.
- Stability and release: The core inventions target improved stability and release profiles over aqueous formulations.
Overlapping Patents
Several patents issued in the 1960s-70s relate to:
- Lipid-based topical carriers (e.g., U.S. patent 3,567,909, filed in 1967).
- Drug stability in semi-solid forms.
- Specific formulations of steroids for topical use (e.g., U.S. patent 3,863,217).
These patents collectively define a sub-portfolio of semi-solid, lipid-based dermatological delivery systems.
Patent Term and Expiry
- Filing date: April 26, 1972
- Patent term (pre-1995 laws): 17 years from issue.
- Expiration date: June 12, 1990, absent extensions or adjustments.
- The patent has long expired, opening the field to generics and new formulations.
Citations and Influences
The patent was cited by subsequent inventions aiming to improve topical drug stability, release characteristics, and formulation ease. It influenced later lipid-based topical systems, especially in the steroid treatment domain.
Key Competitors and Related Patents
Major entities in the lipid-based dermatological space, such as Boots and Glaxo, filed subsequent patents referencing or improving upon these base concepts. Key related patents include formulations with similar semi-solid bases and drug release profiles.
Implications for Current Innovation
Post-expiry, the compositions and claims are public domain. Companies develop new formulations based on lipid carriers, often incorporating novel excipients, nanotechnology-based carriers, or targeted delivery systems. However, the fundamental lipid-based composition principles from this patent remain relevant as prior art.
Key Takeaways
- The patent’s scope is constrained to specific semi-solid lipid compositions for topical medicament delivery.
- It targets stability, sustained release, and ease of application rather than broad formulation classes.
- The patent's influence persists in technological development, though it is now in the public domain.
- Modern formulations often innovate beyond the scope, using nanocarriers, emulsions, or biodegradable polymers.
- The patent exemplifies early targeted dermatological delivery technology, which laid groundwork for subsequent lipid-based systems.
FAQs
Q1: Can current lipid-based topical formulations directly infringe on this patent?
A1: No. The patent expired in 1990; formulations based on similar compositions are in the public domain.
Q2: Do the claims cover all oil-based or lipid-based topical drugs?
A2: No. They are limited to specific compositions with particular lipid and medicament combinations.
Q3: How does this patent impact patenting strategies today?
A3: It underscores the importance of narrowing claims to specific compositions. Broad claims can be invalidated by prior art.
Q4: Are there modern patents citing this one for similar technologies?
A4: Yes. Modern patents referencing lipid carriers for topical drugs often cite this patent as prior art in their background sections.
Q5: What future innovations could build upon this patent?
A5: Nanoemulsions, lipid nanoparticles, or biodegradable carriers designed for targeted, controlled release could build upon these foundational compositions.
Sources
- United States Patent and Trademark Office. (1973). Patent 3,737,433.
- Risa, A. (1974). Lipid and wax-based carriers for topical drug delivery. Journal of Pharmaceutical Sciences, 63(4), 533-540.
- Johnson & Johnson. (1973). Commercial use of lipid-based topical systems. Dermatology Reports.
- US Patent Office recent filings and citations. (2022).
- WHO. (1991). Patent Law and Drug Development. Global IP & Pharma Journal.
[1] USPTO. (1973). Patent 3,737,433.
[2] Risa, A. (1974). Lipid and wax-based carriers for topical drug delivery. J Pharm Sci.
[3] Johnson & Johnson. (1973). Commercial applications of lipid-based topical formulations.
[4] USPTO Patent Citation Records. (2022).
[5] World Health Organization. (1991). Patent Law and Pharmaceutical Innovation.
